SG11201701039PA - Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 - Google Patents

Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1

Info

Publication number
SG11201701039PA
SG11201701039PA SG11201701039PA SG11201701039PA SG11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA SG 11201701039P A SG11201701039P A SG 11201701039PA
Authority
SG
Singapore
Prior art keywords
antibodies
human
combination therapy
activating
antibodies against
Prior art date
Application number
SG11201701039PA
Inventor
Emily Rana Corse
Olivier Freytag
Christian Gerdes
Clech Marine Le
Hyam Levitsky
Marion Ott
Martin Stern
Xu Wei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15159611.1A external-priority patent/EP3070102A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201701039PA publication Critical patent/SG11201701039PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG11201701039PA 2014-08-14 2015-08-11 Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 SG11201701039PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181067 2014-08-14
EP15159611.1A EP3070102A1 (en) 2015-03-18 2015-03-18 Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
PCT/EP2015/068404 WO2016023875A1 (en) 2014-08-14 2015-08-11 Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1

Publications (1)

Publication Number Publication Date
SG11201701039PA true SG11201701039PA (en) 2017-03-30

Family

ID=53800992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201701039PA SG11201701039PA (en) 2014-08-14 2015-08-11 Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1

Country Status (14)

Country Link
US (3) US20160045597A1 (en)
EP (2) EP3626740A1 (en)
JP (1) JP6586454B2 (en)
KR (1) KR20170035945A (en)
CN (1) CN106659780A (en)
AU (1) AU2015303239A1 (en)
BR (1) BR112016029334A2 (en)
CA (1) CA2949739A1 (en)
IL (1) IL249189A0 (en)
MX (1) MX2017001976A (en)
RU (1) RU2017108173A (en)
SG (1) SG11201701039PA (en)
TW (1) TW201609141A (en)
WO (1) WO2016023875A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
CA2978942A1 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
WO2016197367A1 (en) 2015-06-11 2016-12-15 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CA3006529A1 (en) 2016-01-08 2017-07-13 F. Hoffmann-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
EP4035681A1 (en) 2016-01-28 2022-08-03 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical composition for the treatment of cancer
JP7461741B2 (en) 2016-06-20 2024-04-04 カイマブ・リミテッド Anti-PD-L1 and IL-2 Cytokines
BR112019017753A2 (en) * 2017-04-04 2020-04-07 Hoffmann La Roche bispecific molecule, polynucleotide, vector, cell, methods for the production of a molecule and for the treatment of an individual, composition and use of the bispecific molecule
EP3609537A1 (en) * 2017-04-13 2020-02-19 H. Hoffnabb-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
CN111246867B (en) * 2017-06-01 2024-04-12 阿卡米斯生物公司 Oncolytic viruses and methods
JP2021518843A (en) * 2018-03-23 2021-08-05 ザ ユニバーシティ オブ ウエスタン オーストラリア Immunotherapeutic drug treatment method
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
AR117091A1 (en) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co MONOCLONAL ANTIBODIES ANTAGONISTS AGAINST CD40 AND THEIR USES
CN113677365A (en) * 2019-01-22 2021-11-19 瑞伟生物科技公司(美国) Novel anti-CD 40 antibodies
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
AU2022207624A1 (en) 2021-01-13 2023-07-13 F. Hoffmann-La Roche Ag Combination therapy
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (en) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. Immune cells engineered to promote thananotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP3222634A1 (en) * 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PE20120341A1 (en) 2008-12-09 2012-04-24 Genentech Inc ANTI-PD-L1 ANTIBODIES AND ITS USE TO IMPROVE T-CELL FUNCTION
MY193562A (en) * 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
AU2013201121A1 (en) * 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Also Published As

Publication number Publication date
WO2016023875A1 (en) 2016-02-18
MX2017001976A (en) 2017-08-02
BR112016029334A2 (en) 2018-01-09
CA2949739A1 (en) 2016-02-18
CN106659780A (en) 2017-05-10
RU2017108173A3 (en) 2019-03-11
EP3180357B1 (en) 2019-07-03
EP3180357A1 (en) 2017-06-21
EP3626740A1 (en) 2020-03-25
JP6586454B2 (en) 2019-10-02
RU2017108173A (en) 2018-09-17
US20160045597A1 (en) 2016-02-18
IL249189A0 (en) 2017-01-31
US20200095313A1 (en) 2020-03-26
JP2017529327A (en) 2017-10-05
US20180051077A1 (en) 2018-02-22
AU2015303239A1 (en) 2016-12-15
KR20170035945A (en) 2017-03-31
TW201609141A (en) 2016-03-16

Similar Documents

Publication Publication Date Title
IL249189A0 (en) Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1
IL279001A (en) Nasal drug products and methods of their use
IL274568A (en) Cot modulators and methods of use thereof
HK1217021A1 (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1 csf-1r pd-l1
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
EP3177199A4 (en) Medical devices and methods of placement
GB201418350D0 (en) Dispenser and methods of use thereof
GB201403093D0 (en) Therapeutic compounds and their use
GB201404470D0 (en) Therapeutic methods and materials
EP3183010A4 (en) Devices for treating medical waste and methods of their use
IL265955A (en) Therapeutic compounds and methods of use thereof
EP3134108A4 (en) Agents and methods of treatment
EP3145573A4 (en) Portable medical treatment system and method of use
EP3154442A4 (en) Tissue retractor and methods of use
HK1258056A1 (en) Therapeutic compounds and methods of use thereof
IL251135A (en) Method for the synthesis of hydroxy-triglycerides and use thereof for the prevention and treatment of diseases
EP3119307A4 (en) Skin treatment devices and methods
GB201404610D0 (en) Preparation and method for the treatment of skin
AU2014901480A0 (en) Agents and methods of treatment
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use